Abbreviations used in clinical trials: Difference between revisions
Created page with "ABI Ankle-brachial index ACC American College of Cardiology ACCORD Action to Control Cardiovascular Risk in Diabetes ACS Acute coronary syndrome AE Adverse event AHA American..." |
No edit summary |
||
Line 1: | Line 1: | ||
ABI Ankle-brachial index | ABI Ankle-brachial index | ||
ACC American College of Cardiology | ACC American College of Cardiology | ||
ACS Acute coronary syndrome | ACS Acute coronary syndrome | ||
AE Adverse event | AE Adverse event | ||
AHA American Heart Association | AHA American Heart Association | ||
AIDS Acquired immune deficiency syndrome | AIDS Acquired immune deficiency syndrome | ||
ALT Alanine aminotransferase | ALT Alanine aminotransferase | ||
AP Angina pectoris | AP Angina pectoris | ||
apo B Apolipoprotein B | |||
apo B Apolipoprotein B | |||
APOC3 Apolipoprotein C3 | APOC3 Apolipoprotein C3 | ||
AST Aspartate aminotransferase | AST Aspartate aminotransferase | ||
ATP Adult Treatment Panel | ATP Adult Treatment Panel | ||
BMI Body mass index | BMI Body mass index | ||
BUN Blood urea nitrogen | BUN Blood urea nitrogen | ||
CABG Coronary artery bypass graft | CABG Coronary artery bypass graft | ||
CAD Coronary artery disease | CAD Coronary artery disease | ||
CBC Complete blood count | CBC Complete blood count | ||
CEC Clinical Endpoint Committee | CEC Clinical Endpoint Committee | ||
CHD Coronary heart disease | CHD Coronary heart disease | ||
CHF Congestive heart failure | CHF Congestive heart failure | ||
CI Confidence interval | CI Confidence interval | ||
CK-MB Creatine kinase-MB fraction | CK-MB Creatine kinase-MB fraction | ||
CrCL Creatinine clearance | CrCL Creatinine clearance | ||
CRF Case report form | CRF Case report form | ||
CV Cardiovascular | CV Cardiovascular | ||
CVD Cardiovascular disease | CVD Cardiovascular disease | ||
DHA Docosahexaenoic acid | |||
DMC Data Monitoring Committee | DMC Data Monitoring Committee | ||
EC Independent Ethics Committee | EC Independent Ethics Committee | ||
ECG Electrocardiogram | ECG Electrocardiogram | ||
EDC Electronic data capture | EDC Electronic data capture | ||
eGRF Estimated glomerular filtration rate | eGRF Estimated glomerular filtration rate | ||
EPA Eicosapentaenoic acid | EPA Eicosapentaenoic acid | ||
Ethyl-EPA | |||
Ethyl-EPA ethyl eicosapentaenoic acid | |||
EU European Union | |||
FBG Fasting blood glucose | FBG Fasting blood glucose | ||
FDA United States Food and Drug Administration | FDA United States Food and Drug Administration | ||
FSH Follicle-stimulating hormone | FSH Follicle-stimulating hormone | ||
GCP Good Clinical Practice | GCP Good Clinical Practice | ||
GGT Gamma-glutamyl transferase | GGT Gamma-glutamyl transferase | ||
GMP Good Manufacturing Practice | GMP Good Manufacturing Practice | ||
GWAS Genome-wide association study | GWAS Genome-wide association study | ||
HbA1c Hemoglobin A1c | HbA1c Hemoglobin A1c | ||
Hct Hematocrit | Hct Hematocrit | ||
HDL-C High-density lipoprotein cholesterol | HDL-C High-density lipoprotein cholesterol | ||
HF Heart failure | HF Heart failure | ||
Hgb Hemoglobin | |||
Hgb Hemoglobin | |||
HIV Human immunodeficiency virus | HIV Human immunodeficiency virus | ||
HR Hazard ratio | HR Hazard ratio | ||
hs-CRP High-sensitivity C-reactive protein | hs-CRP High-sensitivity C-reactive protein | ||
hsTnT High-sensitivity troponin T | hsTnT High-sensitivity troponin T | ||
HTG Hypertriglyceridemia | HTG Hypertriglyceridemia | ||
ICF Informed consent form | ICF Informed consent form | ||
ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use | ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use |
Revision as of 18:58, 24 October 2019
ABI Ankle-brachial index
ACC American College of Cardiology
ACS Acute coronary syndrome
AE Adverse event
AHA American Heart Association
AIDS Acquired immune deficiency syndrome
ALT Alanine aminotransferase
AP Angina pectoris
apo B Apolipoprotein B
APOC3 Apolipoprotein C3
AST Aspartate aminotransferase
ATP Adult Treatment Panel
BMI Body mass index
BUN Blood urea nitrogen
CABG Coronary artery bypass graft
CAD Coronary artery disease
CBC Complete blood count
CEC Clinical Endpoint Committee
CHD Coronary heart disease
CHF Congestive heart failure
CI Confidence interval
CK-MB Creatine kinase-MB fraction
CrCL Creatinine clearance
CRF Case report form
CV Cardiovascular
CVD Cardiovascular disease
DHA Docosahexaenoic acid
DMC Data Monitoring Committee
EC Independent Ethics Committee
ECG Electrocardiogram
EDC Electronic data capture
eGRF Estimated glomerular filtration rate
EPA Eicosapentaenoic acid
Ethyl-EPA ethyl eicosapentaenoic acid
EU European Union
FBG Fasting blood glucose
FDA United States Food and Drug Administration
FSH Follicle-stimulating hormone
GCP Good Clinical Practice
GGT Gamma-glutamyl transferase
GMP Good Manufacturing Practice
GWAS Genome-wide association study
HbA1c Hemoglobin A1c
Hct Hematocrit
HDL-C High-density lipoprotein cholesterol
HF Heart failure
Hgb Hemoglobin
HIV Human immunodeficiency virus
HR Hazard ratio
hs-CRP High-sensitivity C-reactive protein
hsTnT High-sensitivity troponin T
HTG Hypertriglyceridemia
ICF Informed consent form
ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
IFCC International Federation of Clinical Chemistry
IMP Investigational medicinal product
IQR Interquartile range
IRB Institutional Review Board
ITT Intent-to-Treat
IWRS Interactive Web Response System
JAS Japanese Atherosclerosis Society
JELIS Japan Eicosapentaenoic Acid Lipid Intervention Study LBBB Left bundle branch block
LDL-C Low-density lipoprotein cholesterol
LOE Lack of efficacy
LpPLA2 Lipoprotein-associated phospholipase A2 LVH Left ventricle hypertrophy
MACE Major adverse coronary event
MARINE Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (TG) Levels ≥ 500 and ≤ 2000 mg/dL
MI Myocardial infarction
mITT Modified Intent-to-Treat
NCEP National Cholesterol Education Program
NGSP National Glycohemoglobin Standardization Program NMR Nuclear magnetic resonance
NSTE-ACS Non-ST-segment elevation acute coronary syndrome O3FA Omega-3 fatty acid
ODIS Off drug in study
OGTT Oral glucose tolerance test
OR Odds ratio
PAD Peripheral arterial disease
PCI Percutaneous coronary intervention PCSK9 Proprotein convertase subtilisin kexin 9 PH Proportional hazard
PI Principal Investigator
PP Per protocol
PROVE-IT Pravastatin or Atorvastatin Evaluation and Infection Therapy PVD Peripheral vascular disease
RBC Red blood cells
REDUCE-IT Reduction of Cardiovascular Events with EPA – Intervention Trial RLP-C Remnant lipoprotein cholesterol
RR Relative risk
SAE Serious adverse event
SAP Statistical Analysis Plan
SC Steering Committee
SPC Summary of Product Characteristics
SUSAR Suspected unexpected serious adverse reaction
TC Total cholesterol
TEAE Treatment-emergent adverse event
TG Triglycerides
TIA Transient Ischemic Attack
TIMI Thrombolysis In Myocardial Infarction
ULN Upper limit of normal
US United States
USPI United States Prescribing Information
VLDL-C Very low density lipoprotein cholesterol
WBC White cell blood count